 Home > Active Ingredient News > Antitumor Therapy > Thorac Cancer: Chemotherapy combined with immunotherapy after progression on osimertinib for advanced NSCLC is superior to chemotherapy alone

Thorac Cancer: Chemotherapy combined with immunotherapy after progression on osimertinib for advanced NSCLC is superior to chemotherapy alone

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

cancer cell cycle

huang long bing disease

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Osimertinib is the standard first-line treatment for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)
.

Resistance after osimertinib treatment remains a clinical challenge

Osimertinib is the standard first-line treatment for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)

A retrospective study was performed in patients with advanced NSCLC after progression on osimertinib
.

The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety of patients in groups IO+C and C were evaluated .

A retrospective study was performed in patients with advanced NSCLC after progression on osimertinib

A total of 40 patients were included in the study

Our results showed that the ORR (45% vs.

The median progression-free survival (PFS) of patients in the IO+C group was significantly longer than that of the patients in the C group (6.

PFS and OS

To determine which patients were most likely to benefit from the addition of immunotherapy, a subgroup analysis of PFS was performed
.

Our results showed that patients ≤65 years of age, liver metastases, adrenal metastases and third-line therapy significantly prolonged PFS in the IO+C group compared with the C group

To determine which patients were most likely to benefit from the addition of immunotherapy, a subgroup analysis of PFS was performed

PFS subgroup analysis

Subgroup analysis was then performed
.

Similar to the results of PFS, our results showed that in the IO+C group, patients ≤65 years of age, adrenal metastases, exon 19 del mutations, and third-line therapy had longer OS than the C group, regardless of gender

Subgroup analysis was then performed

OS subgroup analysis

TRAEs were reported in 85% and 90% of patients in groups IO+C and C, respectively
.

In conclusion, the study showed that chemotherapy combined with immunotherapy after osimertinib treatment for advanced NSCLC improved the prognosis of patients compared with chemotherapy alone
.

Studies have shown that chemotherapy combined with immunotherapy after progression on osimertinib in advanced NSCLC improves the prognosis of patients compared with chemotherapy alone
.
Studies have shown that chemotherapy combined with immunotherapy after progression on osimertinib in advanced NSCLC improves the prognosis of patients compared with chemotherapy alone
.

Original source:

Long Y, Xiong Q, Song Q, Li Y, Li X, Qin B, Huang Z, Hu Y, Yang B.
Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib.
Thorac Cancer.
2021 Dec 27.
doi: 10.
1111/1759-7714.
14271.
Epub ahead of print.
PMID: 34958168.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.